Gujarat Kidney And Super Speciality Limited's 7th AGM Passes All Resolutions Unanimously
Gujarat Kidney And Super Speciality Limited's 7th AGM on September 28, 2026, saw all resolutions pass unanimously. Key approvals included financial statements, director appointments (Mrs. Anita Bharpoda, Mr. Paresh Dhoti, Mrs. Disha Bharpoda), revised director remuneration, and corporate actions under the Companies Act.
The passing of multiple resolutions related to financial statements, director appointments, remuneration, and corporate actions signifies important governance and operational decisions, impacting the company's future direction.
All resolutions were passed unanimously, indicating strong shareholder support for the company's decisions and management.
Gujarat Kidney And Super Speciality Limited announced that all resolutions presented at its 7th Annual General Meeting (AGM) were passed with the requisite majority. The AGM was held on Monday, September 28, 2026, commencing at 9:30 a.m. and concluding at 9:50 a.m. at the company's registered office in Vadodara.
The resolutions included the adoption of standalone and consolidated financial statements for FY 2025-26, the appointment of Mrs. Anita Bharpoda as a Director retiring by rotation, the appointment of a secretarial auditor, and the appointment of Mr. Paresh Dhoti and Mrs. Disha Bharpoda as Independent Directors. Additionally, the shareholders approved the revision in remuneration for Mr. Pragnesh Bharpoda (Managing Director) and Mrs. Bharti Bharpoda (Wholetime Director). Special resolutions were also passed concerning approvals under sections 180(1)(c), 180(1)(a), 186, and 185 of the Companies Act, 2013, related to borrowing powers, investments, and loan advancements. Finally, related party transactions were also approved.
The company submitted the voting results and the Scrutinizer's Report as per Regulation 44(3) of the SEBI (LODR) Regulations, 2015.
What to do with a filing like this
Gujarat Kidney And Super Speciality Limited filed this with the NSE as a statutory disclosure, categorised under agm. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Gujarat Kidney And Super Speciality Limited. Read the original for the full detail.